Tetanus Toxin Fragment for Rapid Antidepressant Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antidepressants for depression, particularly those for depression associated with Parkinson's disease, have limited efficacy, delayed onset, and undesirable side effects, highlighting the need for rapid onset and more effective treatments that also address neurotrophic and inflammatory processes.
Innovation Solution
The C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) is administered to decrease immobility scores in animal models of depression, increasing central brain-derived neurotrophic factor (BDNF) and decreasing tumor necrosis factor-alpha (TNF-alpha) in the hippocampus and frontal cortex, suggesting its potential as a novel antidepressant.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antidepressants (TCAs, MAOIs, NRIs, SSRIs) are administered, then depression symptoms are relieved, but onset is delayed and side effects occur
Solution Approach 1:
The patent segments the tetanus toxin into a specific non-toxic fragment (Hc fragment, amino acids 975-1315) that retains antidepressant activity. This segmentation allows isolation of the therapeutic component without the harmful effects of the complete toxin, enabling rapid-acting antidepressant treatment without the delayed onset characteristic of conventional medications.
2Reliability
If conventional antidepressants are administered, then depression symptoms are relieved, but undesirable side effects occur
Solution Approach 1:
The patent extracts and utilizes only the Hc fragment (amino acids 975-1315) of the tetanus toxin, which contains the antidepressant activity, while leaving behind the toxic portions of the molecule. This extraction principle enables the therapeutic effect to be achieved without the harmful side effects associated with complete toxins or conventional antidepressants.
3Reliability
If Hc-TeTx is administered, then immobility scores decrease and BDNF increases, but the mechanism of rapid action needs clarification
Solution Approach 1:
The patent utilizes parameter changes in neurotrophic factors (specifically BDNF levels) and inflammatory markers (TNF-alpha) to explain the rapid antidepressant mechanism. By measuring and utilizing these biochemical parameters, the patent clarifies how Hc-TeTx produces rapid antidepressant effects without requiring complex mechanistic explanations.
Data Source
AI summary
C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) provides therapeutic effects in motor impairments associated with Parkinson disease (PD), and provides long lasting antidepressant effects, thus useful in treating and mitigating depression, particularly PD-depression co-morbid condition. A method for treating or mitigating depression, including administrating an effective amount of C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) to a subject in need thereof. A method for treating or mitigating motor impairments associated with Parkinson's disease (PD), including administrating an effective amount of C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) to a subject in need thereof.